Headache and female hormones: what you need to know
- 1 June 2001
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 14 (3) , 323-333
- https://doi.org/10.1097/00019052-200106000-00010
Abstract
The normal female lifecycle is associated with hormonal milestones, including menarche, pregnancy, contraceptive use, menopause, and the use of replacement sex hormones. Attacks of migraine without aura, but not with aura, are more likely to occur 2 days before onset and on the first 2 days of menses, but they are not more severe than those that occur outside the perimenstrual period. Oral sumatriptan and naratriptan are effective as short-term perimenstrual prophylaxis. Postdural headache can occur during the postpartum period. The International Headache Society Task Force assessed the efficacy of treatment of women who had migraine with combined oral contraceptives and hormone replacement therapy, as well as the risk of ischemic stroke associated with their use. There is no contraindication to the use of oral contraceptives in women with migraine in the absence of migraine aura or other risk factors. There is a potentially increased risk of ischemic stroke in women with migraine who are using combined oral contraceptives and have additional risk factors that cannot easily be controlled, including migraine with aura. There is no compelling evidence that postmenopausal hormone replacement therapy either decreases or increases stroke risk.Keywords
This publication has 49 references indexed in Scilit:
- Recommendations on the Risk of Ischaemic Stroke Associated With Use of Combined Oral Contraceptives and Hormone Replacement Therapy in Women With MigraineCephalalgia, 2000
- Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activityFertility and Sterility, 1999
- Treatment of menstruation-associated migraine with the nonprescription combination of acetaminophen, aspirin, and caffeine: Results from three randomized, placebo-controlled studiesClinical Therapeutics, 1999
- An open-label, multicenter, noncomparative safety and efficacy study of Mircette™, a low-dose estrogen-progestin oral contraceptiveAmerican Journal of Obstetrics and Gynecology, 1998
- Premenstrual Syndrome — Pathophysiologic ConsiderationsNew England Journal of Medicine, 1998
- Contraceptive outcomes among adolescents prescribed Norplant implants versus oral contraceptives after one year of useAmerican Journal of Obstetrics and Gynecology, 1997
- Postpartum bilateral subdural hematomas following spinal anesthesia: Case reportSurgical Neurology, 1997
- Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular DiseaseNew England Journal of Medicine, 1996
- Preliminary experience with Norplant® in an inner city populationContraception, 1993
- Ascending back pain and headache during attempted epidural placementJournal of Clinical Anesthesia, 1991